前立腺がん治療薬の世界市場:インサイト・疫学・市場予測

◆英語タイトル:Prostate cancer- Market Insight, Epidemiology and Market Forecast -2030
◆商品コード:DELV20JU003
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(3名様閲覧)USD9,500 ⇒換算¥997,500見積依頼/購入/質問フォーム
Three UserUSD14,250 ⇒換算¥1,496,250見積依頼/購入/質問フォーム
Site LicenseUSD19,000 ⇒換算¥1,995,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s “Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Prostate cancer market report provides current treatment practices, emerging drugs, Prostate cancer market share of the individual therapies, current and forecasted Prostate cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Prostate cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Prostate cancer Disease Understanding and Treatment Algorithm
Prostate cancer a type of malignancy that occurs in the prostate gland. The prostate is a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is located next to the bladder and can be examined by getting a digital rectal exam.

Prostate cancer is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. According to the Cancer Treatment Centers of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation. The symptoms of prostate cancer do not usually appear until the prostate is large enough to affect the tube that carries urine from the bladder out of the penis. Clinical Stage and treatment pattern are key factors in Prostate Cancer.

“In clinical-stage-wise cases of Prostate Cancer, most of the cases were of the localized stage, which accounted for approximately 60% of the total diagnosed prevalent cases in 2017. On the other hand, metastatic cases accounted for only 7% of the total diagnosed prevalent cases.”

Diagnosis

Many patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI. Screening is a type of testing to find cancer in people before they have symptoms. It is not clear, however, if the benefits of prostate cancer screening outweigh the risks for most men. Still, after discussing the pros and cons of screening with their doctors, some men might reasonably choose to be screened. If the result of one of these tests is abnormal, patients will probably need a prostate biopsy to know for sure the occurrence of cancer.

Treatment

The prostate cancer experts develop a comprehensive treatment plan for each patient specifically. Treatment strategies of prostate cancers depend on the stage and progression of cancer. However, prostate cancer often grows slowly, and active surveillance may be the preferred treatment option for some men, with the oncologist closely monitoring the disease with tests and holding off on treatment until a later date. Besides, other treatment options for prostate cancers include chemotherapy, hormone therapy, immunotherapy, radiation therapy, and surgery.

Patients who have never received, i.e., are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). Further down the line, many prostate cancers patients ultimately fail to respond to ADT and are termed castrate-resistant prostate cancer (CRPC).

“It was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic castrate sensitive prostate cancer (nmCSPC/ nmHSPC). Contrary to this near to 22% of biochemical recurrence/ progressive cases progresses to be non-metastatic castrate resistant prostate cance (nmCRPC). Of the metastatic prostate cancer cases, approximately 55% have mCSPC/ mHSPC, and round to 45% progresses to be mCRPC.”

Prostate cancer Epidemiology
The Prostate cancer epidemiology division provide insights about historical and current Prostate cancerpatient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 cases in 2017, and are expected to increase during the study period.
The disease epidemiology covered in the report provides historical as well as forecasted Prostate Cancer epidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed cases of Prostate Cancer patients by Clinical Stages, Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC, Total Treated cases of Non-metastatic CSPC/HSPC and CRPC, Total Treated Cases of metastatic HSPC/CSPC, and CRPC] scenario of Prostate Cancer in the 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Prostate cancer Epidemiology

Estimates show the highest diagnosed population of Prostate Cancer is in the United States. in EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 360,916 cases in 2017, followed by France and Italy.
Our estimation suggested that the total treated patient pool of mCSPC/HSPC was 75,600 in 2017, will likely increase throughout the study period, besides nearly 73,452 cases of mCRPC treated in first-line.
According to the DelveInsight, in 2017, total treated pool nmCRPC progressed from first-line to the second-line was found to be 160,287 in the 7MM. On the other hand, the total treated patient pool of nmCSPC/HSPC was 668,577 cases in the 7MM (2017).
Prostate cancer Drug Chapters
Drug chapter segment of the Prostate cancer report encloses the detailed analysis of Prostate cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Prostate cancerclinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Xtandi (Enzalutamide): Astellas Pharma/Pfizer

It is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. It is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), and metastatic castration-sensitive prostate cancer (mCSPC). Xtandi approved initially in August 2012. It was approved by the US FDA for the treatment of patients with mCRPC who have previously received docetaxel. In December 2019, Pfizer and Astellas Pharma announced that the US FDA has approved a supplemental New Drug Application (sNDA) for Xtandi for the treatment of patients with mCSPC.

Erleada (apalutamide): Janssen Pharmaceutical

Janssen Pharmaceutical’s product Erleada (apalutamide) is a next-generation oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). It is taken orally, once daily, with or without food. Erleada inhibits the growth of cancer cells in three ways: by preventing the binding of androgen to the AR; by stopping the AR from entering the cancer cells; and by preventing the AR from binding to the DNA of the cancer cell. In January 2020, the European Commission has approved apalutamide (Erleada) for use in combination with androgen deprivation therapy (ADT) for the treatment of adult men with metastatic hormone-sensitive prostate cancer. The EC approval is based on data from the phase III TITAN study, which assessed the addition of apalutamide to ADT in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis.

Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation

Bayer HealthCare/Orion Corporation’s product Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) with a distinct chemical structure that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. Nubeqa is approved for the treatment of patients with nmCRPC. In January 2020, the Japanese Ministry of Health, Labor and Welfare (MHLW) granted marketing authorization to Nubeqa for the treatment of men with nmCRPC. Nubeqa (darolutamide) is also being investigated for mHSPC/mCSPC.In ARASENS trial, approximately 1,300 subjects enrolled with mHSPC. The patients will be randomized (1:1 ratio) to receive 600 mg (2 × 300 mg tablets) of Darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total daily dose of 1,200 mg, in addition to standard ADT and docetaxel. Subjects will be stratified at randomization for the extent of disease and for Alkaline Phosphatase levels.

Products detail in the report…

Prostate cancer Emerging Drugs

Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme

Lynparza (olaparib) is first and best-in-class oral poly ADP-ribose polymerase (PARP) inhibitor, and the ¬first targeted treatment to block DDR in tumours harbouring a deficiency in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2. AstraZeneca have global strategic oncology collaboration with Merck to co-develop and co-commercialize Lynparza. Recently in January 2020, the US FDA accepted the supplemental New Drug Application for Lynparza and granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, which have progressed following prior treatment with a new hormonal agent. A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020. The priority review is based on the results from the Phase III PROfound trial, which were presented during the Presidential Symposium at the 2019 European Society of Medical Oncology congress.

Talzoparib: Pfizer/Astellas Pharma

Talzoparib (Pfizer/Astellas Pharma) is an orally PARP inhibitor with potential antineoplastic activity, currently under evaluation in Phase III clinical stage. It selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. A phase III study (NCT03395197; TALAPRO-2) was initiated to compare rPFS in men with mCRPC treated with Talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of Talazoparib in combination with enzalutamide (Xtandi).

Rubraca (Rucaparib): Clovis Oncology

Clovis Oncology is investigating one of their lead candidates named Rubraca (Rucaparib) for various cancer indications. It is an oral, small-molecule inhibitor of PARP1, PARP2 and PARP3 being developed in Prostate Cancer, and Ovarian Cancer as well as several additional solid tumor indications. It is worth mentioning that, the US Food and Drug Administration has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of May 15, 2020.

Keytruda: Merck Sharp & Dohme

Merck Sharp & Dohme’s immunotherapy Keytruda, also known as pembrolizumab, is a PD-1 blocking antibody. It is mainly used for cancers that are advanced, have spread to other parts of the body or are not responding to other treatments. This is currently being investigated in Phase III clinical trials in combination with Enzalutamide for the treatment of patients affected by mHSPC. Moreover, several other trials are also ongoing for the treatment of patients affected with mCRPC.

Ipatasertib (RG7440): Hoffmann-La Roche

Hoffmann-La Roche investigating Ipatasertib (RG7440) for Prostate Cancer. It is a small molecule Pan-Akt inhibitor which is under investigation by Roche in Phase III clinical trial. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

ProstAtak: Advantagene

Advantagene is developing ProstAtak for the treatment of patients suffering from prostate cancer. ProstAtak jump-starts the body’s own immune system to detect and destroy recurring cancer cells. The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the “ULYSSES” trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). However, enrollment is still open for prostate cancer patients choosing radiation therapy as their primary treatment (PrTK03- NCT01436968).

177Lu-PSMA-617: Novartis

177Lu-PSMA-617 is an investigational radioligand therapy (RLT) in development for mCRPC by Novartis. Currently this drug is in a Phase III trial (VISION) for the treatment of patients with progressive PSMA-positive mCRPC.

Products detail in the report…

Prostate Cancer MarketProstate cancer Market Outlook
The Prostate cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Prostate cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Prostate cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Prostate cancer market in 7MM is expected to change in the study period 2017-2030.

Key Findings

According to DelveInsight, Prostate Cancer market in the 7MM is expected to change in the study period 2017–2030.

Country Wise Market Outlook

According to the estimates, the highest market size of Prostate Cancer is found in the United States followed by the Germany and Japan in 2017 in the seven major markets.

Prostate cancer Drugs Uptake
In mCSPC, currently market is dominated by hormonal therapies, mainly the first-generation hormonal therapies however label expansion of Xtandi and abiraterone acetate, approval of Erleada in mCSPC expected to help in driving the overall market of CSPC.
Likewise, in nmCSPC also market is also mainly dominated by first-generation hormonal therapies. However, in future nmCSPC market size will be mainly driven by expected launch of ProstAtak and RV001.
In metastatic CRPC, the current market is mainly dominated by Zytiga and Xtandi.
In non-metastatic CRPC, Erleada with better clinical profile and early mover advantage will expect to generate maximum revenue in this setting
Prostate cancer Pipeline Development Activities
The drugs which are in pipeline includes:

1. Lynparza: Pre-registration

2. Rucaparib: Pre-registration

3. Opdivo (nivolumab): Phase III

4. 177Lu-PSMA-617: Phase III

5. Niraparib ± Abiraterone Acetate: Phase III

6. HC-1119 (Deuterated form of enzalutamide) : Phase III

7. Ipatasertib (RG7440) + Abiraterone Acetate: Phase III

8. Talazoparib ± Enzalutamide: Phase III

9. ProstAtak (AdV-tk) + valacyclovir: Phase III

10. Relugolix: Phase III

11. Capivasertib: Phase II

12. Seviteronel: Phase II

13. PRX302 (topsalysin) Phase II

14. RV001: Phase II

Product details and complete list of emerging products will be provided in the full report…

Pipeline Development Activities

Key Points

In January 2020, the US FDA accepted the sNDA for Lynparza and granted Priority Review in the US for patients with mCRPC and deleterious or suspected deleterious germline or somatic HRR gene mutations, which have progressed following prior treatment with a new hormonal agent.
It is worth mentioning that, the US FDA has accepted the company’s sNDA for Rubraca and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of May 15, 2020. Clovis submitted the NDA submission for Rucaparib as monotherapy treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer in November 2019.
Reimbursement Scenario in Prostate cancer
In May 2019, Xtandi (enzalutamide) was not recommended, within its marketing authorization, treating high-risk hormone-relapsed non-metastatic prostate cancer in adults by National Institute for Health and Care Excellence (NICE).
In March 2017, Zytiga (abiraterone acetate) received was favorable decision from the Haute Autorité de santé (HAS), within its marketing authorization for asymptomatic or low symptom castration-resistant metastatic prostate cancer in patients who failed androgen deprivation therapy.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Prostate cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Prostate cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Prostate cancer Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of Prostate cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Prostate cancer epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Prostate cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Prostate cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Prostate cancer market

Report Highlights
In the coming years, Prostate cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Prostate cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Prostate cancer. Launch of emerging therapies will significantly impact the Prostate cancer market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Prostate cancer
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Prostate cancer Report Insights
Prostate cancer Patient Population
Prostate cancer Therapeutic Approaches
Prostate cancer Pipeline Analysis
Prostate cancer Market Size and Prostate cancer Market Trends
Prostate cancer Market Opportunities
Impact of upcoming Therapies

Prostate cancer Report Key Strengths
11 Years Forecast
Prostate cancer 7MM Coverage
Prostate cancer Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Prostate cancer Market
Prostate cancer Drugs Uptake

Prostate cancer Report Assessment
Current Prostate cancer Treatment Practices
Prostate cancer Unmet Needs
Prostate cancer Pipeline Product Profiles
Prostate cancer Market Attractiveness
Prostate cancer Market Drivers and Prostate cancer Market Barriers

Key Questions
Market Insights:

What was the Prostate cancer market share (%) distribution in 2017 and how it would look like in 2030?
What would be the Prostate cancer total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Prostate cancer market size during the forecast period (2017-2030)?
At what CAGR, the Prostate cancer market is expected to grow in 7MM during the forecast period (2017-2030)?
What would be the Prostate cancer market outlook across the 7MM during the forecast period (2017-2030)?
What would be the Prostate cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Prostate cancer?
What is the historical Prostate cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Prostate cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Prostate cancer?
Out of all 7MM countries, which country would have the highest prevalent population of Prostate cancer during the forecast period (2017-2030)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
What are the current options for the Prostate cancer treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Prostate cancer in the USA, Europe, and Japan?
What are the Prostate cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Prostate cancer?
How many therapies are developed by each company for Prostate cancer treatment?
How many are emerging therapies in mid-stage, and late stage of development for Prostate cancer treatment?
What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Prostate cancer therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Prostate cancer and their status?
What are the key designations that have been granted for the emerging therapies for Prostate cancer?
What are the global historical and forecasted market of Prostate cancer?

Reasons to buy
The Prostate cancer Market report will help in developing business strategies by understanding trends shaping and driving the Prostate cancer market
To understand the future market competition in the Prostate cancer market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Prostate cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Prostate cancer market
To understand the future market competition in the Prostate cancer market

What is Prostate Cancer?

Prostate Cancer is a cancer of prostate gland, which is a part of male reproductive system. It is the fourth most common worldwide and third most prevalent type of cancer in the US.

At what CAGR is Prostate Cancer Market size expected to grow for the study period of 2017-30?

Prostate Cancer Market size is expected to increase at a CAGR of 8.1% for the study period 2017-30.

Which country is expected to dominate the Prostate Cancer Market in the 7MM?

Among 7MM countries, the US is anticipated to occupy the most substantial chunk of the Prostate Cancer Market size by 2030.

What is the Prostate Cancer prevalence expected by the end of 2020 in the 7MM?

Prostate Cancer prevalence in the 7MM is expected to reach 7,494,882 by 2020.

Which country is expected to account for the most significant prevalent cases for Prostate Cancer in the 7MM?

The US is expected to account for the highest Prostate Cancer prevalent cases.

How is the epidemiology of Prostate Cancer segmented?

Prostate Cancer epidemiology is segmented into Age-Specific Cases of Prostate Cancer, Total Treated Cases of mHSPC/CSPC and CRPC, Total Non-Metastatic and Metastatic Cases of CSPC/HSPC and CRPC, Total Diagnosed Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages and Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC for the study period of 2017-30 for the 7MM.

What are the therapies available in the Prostate Cancer market?

The marketed therapies in the Prostate Cancer market are Xofigo (radium Ra 223 dichloride) of Bayer Health Care, Xtandi (Enzalutamide) of Astellas Pharma, Amgen’s Prolia (denosumab), Janssen’s Erleada (apalutamide), Sanofi’s Jevtana (Cabazitaxel) and Nubeqa (Darolutamide/ODM-201) of Bayer HealthCare/Orion Corporation.

What are the key companies working to advance the Prostate Cancer market?

AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, and Merck Sharp & Dohme along with others are the major pharma companies working to fuel the Prostate Cancer market.

What are the emerging therapies in the Prostate Cancer Pipeline for the study period of 2017-30?

Prostate Cancer Pipeline appears robust comprising Lynparza, Rucaparib, Opdivo (nivolumab), 177Lu-PSMA-617, Niraparib ± Abiraterone Acetate, HC-1119 (Deuterated form of enzalutamide), Ipatasertib (RG7440) + Abiraterone Acetate, Talazoparib ± Enzalutamide, ProstAtak (AdV-tk) + valacyclovir, Relugolix, Capivasertib, Seviteronel, PRX302 (topsalysin), and RV001.

【レポートの目次】

1. Key Insights

2. Executive Summary of Prostate Cancer

3. SWOT Analysis of Prostate Cancer

4. Prostate Cancer Market Overview at a Glance

5. Prostate Cancer: Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of Prostate Cancer

5.1.2. Risk Factors and Causes of Prostate Cancer

5.1.3. Pathophysiology of Prostate Cancer

5.1.4. Prostate Neoplasia

5.1.5. Genetics of Prostate Cancer

6. Diagnosis of Prostate Cancer

6.1. Screening Tests for Prostate Cancer

6.2. Tests to Diagnose Prostate Cancer

6.3. Stages and Grades of Prostate Cancer

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM

7.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM

7.3.3. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM

7.3.4. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the 7MM

7.3.5. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Diagnosed Cases of Prostate Cancer in the United States

7.4.2. Age-specific Cases of Prostate Cancer in the United States

7.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States

7.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the United States

7.4.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the United States

7.4.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the United States

8. EU-5 Country-wise Epidemiology

8.1. Germany

8.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany

8.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany

8.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany

8.1.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Germany

8.1.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Germany

8.1.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Germany

8.2. France

8.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France

8.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France

8.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France

8.2.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in France

8.2.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in France

8.2.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in France

8.3. Italy

8.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy

8.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy

8.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy

8.3.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Italy

8.3.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Italy

8.3.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Italy

8.4. Spain

8.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain

8.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain

8.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain

8.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Spain

8.4.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Spain

8.4.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Spain

8.5. United Kingdom

8.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

8.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

8.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom

8.5.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom

8.5.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in the United Kingdom

8.5.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in the United Kingdom

8.6. Japan

8.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan

8.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan

8.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan

8.6.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in Japan

8.6.5. Total Treated cases of Non-metastatic CSPC/HSPC and CRPC Patients in Japan

8.6.6. Total Treated Cases of Metastatic CSPC/HSPC and CRPC Patients in Japan

9. Current Treatment Practices: Prostate Cancer

9.1. Treatment Algorithm of Prostate Cancer

9.2. Observation or Active Surveillance

9.3. Surgery

9.3.1. Open or Laparoscopic Radical Prostatectomy

9.3.2. Risks of Prostate Surgery

9.4. Radiation Therapy

9.4.1. Types of Radiation Therapy

9.5. Hormone Therapy

9.5.1. Types of Hormone Therapy

9.6. Immunotherapy

9.6.1. Vaccine

9.6.2. Immune checkpoint inhibitors

9.7. Chemotherapy

10. Guideline of Prostate Cancer

10.1. TheEuropean Association of Urology (EAU) Guideline for Management of Prostate Cancer: 2020

10.2. The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer: 2019

10.2.1. Screening Guidelines

10.2.2. Genetic Testing

10.2.3. Bone Scan for Diagnosis of Metastatic Disease

10.2.4. Castration-Resistant Prostate Cancer (CRPC)

10.3. Japanese Urological Association Clinical Practice Guideline for Prostate Cancer

11. Unmet Needs of Prostate Cancer

12. Marketed Therapies

12.1. Key Cross

12.2. Xofigo (radium Ra 223 dichloride): Bayer Health Care

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activities

12.2.4. Pivotal Clinical Trial

12.2.5. Ongoing Current Pipeline Activity

12.3. Xtandi (Enzalutamide): Astellas Pharma

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activities

12.3.4. Pivotal Clinical Trial

12.3.5. Ongoing Current Pipeline Activity

12.4. Prolia (denosumab): Amgen

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Other Developmental Activities

12.4.4. Pivotal Clinical Trial

12.4.5. Summary of Pivotal Trials

12.5. Erleada (apalutamide): Janssen Pharmaceutical

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activities

12.5.4. Pivotal Clinical Trials

12.5.5. Ongoing Current Pipeline Activity

12.6. Jevtana (Cabazitaxel): Sanofi

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Other Developmental Activities

12.6.4. Pivotal Clinical Trials

12.6.5. Ongoing Current Pipeline Activity

12.7. Nubeqa (Darolutamide/ODM-201): Bayer HealthCare/Orion Corporation

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Other Developmental Activities

12.7.4. Pivotal Clinical Trials

12.7.5. Ongoing Current Pipeline Activity

13. Emerging Therapies

13.1. Lynparza (Olaparib): AstraZeneca/ Merck Sharp & Dohme

13.1.1. Product Description

13.1.2. Clinical Development

13.1.3. Safety and Efficacy

13.2. Opdivo (nivolumab): Bristol-Myers Squibb

13.2.1. Product Description

13.2.2. Clinical Development

13.2.3. Safety and Efficacy

13.3. 177Lu-PSMA-617: Novartis

13.3.1. Product Description

13.3.2. Clinical Development

13.3.3. Safety and Efficacy

13.4. Relugolix: Myovant Sciences/Takeda

13.4.1. Product Description

13.4.2. Clinical Development

13.4.3. Safety and Efficacy

13.5. HC-1119: Hinova Pharmaceuticals

13.5.1. Product Description

13.5.2. Clinical Development

13.5.3. Safety and Efficacy

13.6. Seviteronel (VT-464): Innocrin Pharmaceutical

13.6.1. Product Description

13.6.2. Clinical Development

13.6.3. Safety and Efficacy

13.7. PROSTVAC-V/F: Bavarian Nordic

13.7.1. Product Description

13.7.2. Clinical Development

13.8. ODM-208: Orion Pharma

13.8.1. Product Description

13.8.2. Clinical Development

13.8.3. Safety and Efficacy

13.9. Sacituzumab Govitecan (IMMU-132): Immunomedics

13.9.1. Product Description

13.9.2. Clinical Development

13.10. Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme

13.10.1. Product Description

13.10.2. Clinical Development

13.10.3. Safety and Efficacy

13.11. Ipatasertib (RG7440): Hoffmann-La Roche

13.11.1. Product Description

13.11.2. Clinical Development

13.11.3. Safety and Efficacy

13.12. Talazoparib: Pfizer/Astellas Pharma

13.12.1. Product Description

13.12.2. Clinical Development

13.12.3. Safety and Efficacy

13.13. Capivasertib (AZD5363): AstraZeneca

13.13.1. Product Description

13.13.2. Clinical Development

13.13.3. Safety and Efficacy

13.14. AZD4635: AstraZeneca

13.14.1. Product Description

13.14.2. Clinical Development

13.15. PRX302 (topsalysin): Sophiris Bio

13.15.1. Product Description

13.15.2. Clinical Development

13.15.3. Safety and Efficacy

13.16. Pamiparib (BGB-290): BeiGene

13.16.1. Product Description

13.16.2. Clinical Development

13.17. Enoblituzumab (MGA271): MacroGenics

13.17.1. Product Description

13.17.2. Clinical Development

13.17.3. Safety and Efficacy

13.18. Tisotumab Vedotin: Genmab

13.18.1. Product Description

13.18.2. Clinical Development

13.18.3. Safety and Efficacy

13.19. Dupilumab: Regeneron Pharmaceuticals

13.19.1. Product Description

13.19.2. Clinical Development

13.20. Rubraca (Rucaparib): Clovis Oncology

13.20.1. Product Description

13.20.2. Clinical Development

13.20.3. Safety and Efficacy

13.21. Niraparib: Janssen Research & Development

13.21.1. Product Description

13.21.2. Clinical Development

13.21.3. Safety and Efficacy

13.22. Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical

13.22.1. Product Description

13.22.2. Clinical Development

13.22.3. Safety and Efficacy

13.23. Abemaciclib (LY2835219): Eli Lilly and Company

13.23.1. Product Description

13.23.2. Clinical Development

13.24. Tomivosertib (eFT508): eFFECTOR Therapeutics

13.24.1. Product Description

13.24.2. Clinical Development

13.25. Onvansertib: Trovagene

13.25.1. Product Description

13.25.2. Clinical Development

13.25.3. Safety and Efficacy

13.26. RV001V: RhoVac

13.26.1. Product Description

13.26.2. Other Developmental Activities

13.26.3. Clinical Development

13.26.4. Safety and Efficacy

13.27. ProstAtak: Advantagene

13.27.1. Product Description

13.27.2. Other Developmental Activities

13.27.3. Clinical Development

13.27.4. Safety and Efficacy

14. Prostate Cancer: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Outlook: 7MM

15. 7MM Market Size

15.1. Total Market Size of Prostate Cancer in the 7MM

15.2. Total Market size of CSPC by Therapies in the 7MM

15.3. Total Market size of CRPC by Therapies in the 7MM

15.4. United States Market Size

15.4.1. Total Market size of Prostate Cancer in the United States

15.4.2. Total Market size of CSPC by Therapies in the United States

15.4.3. Total Market size of CRPC by Therapies in the United States

15.5. EU-5 Market Size

15.5.1. Germany Market Size

15.5.2. France Market Size

15.5.3. Italy Market Size

15.5.4. Spain Market Size

15.5.5. United Kingdom Market Size

15.6. Japan Market Size

15.6.1. Total Market size of Prostate Cancer in Japan

15.6.2. Total Market size of CSPC by Therapies in Japan

15.6.3. Total Market size of CRPC by Therapies in Japan

16. Market Access and Reimbursement of Prostate Cancer

17. Market Drivers of Prostate Cancer

18. Market Barriers of Prostate Cancer

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Table 1: Summary of Prostate Cancer Market, Epidemiology, and Key Events (2017–2030)

Table 2: Genetic Changes Associated with Prostate Cancer Tumorigenesis

Table 3: Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Table 4: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–203

Table 5: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)

Table 6: Total Metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)

Table 7: Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Table 8: Total Treated Cases of nmCRPC by Line of Therapies in the 7MM (2017–2030)

Table 9: Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)

Table 10: Total Treated Cases of mCRPC by Line of Therapies in the 7MM (2017–2030)

Table 11: Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Table 12: Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Table 13: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States

Table 14: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030

Table 15: Total Metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)

Table 16: Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Table 17: Total Treated Cases of nmCRPC by Line of Therapies in the United States (2017–20

Table 18: Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)

Table 19: Total Treated Cases of mCRPC by Line of Therapies in the United States (2017–203

Table 20: Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 21: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 22: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany

Table 23: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)

Table 24: Total Metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)

Table 25: Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)

Table 26: Total Treated Cases of nmCRPC by Line of Therapies in Germany (2017–2030)

Table 27: Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)

Table 28: Total Treated Cases of mCRPC by Line of Therapies in Germany (2017–2030)

Table 29: Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 30: Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 31: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France

Table 32: Total Non-metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)

Table 33: Total Metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)

Table 34: Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Table 35: Total Treated Cases of nmCRPC by Line of Therapies in France (2017–2030)

Table 36: Total Treated Cases of mHSPC/CSPC in France (2017–2030)

Table 37: Total Treated Cases of mCRPC by Line of Therapies in France (2017–2030)

Table 38: Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 39: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 40: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (

Table 41: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)

Table 42: Total Metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)

Table 43: Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Table 44: Total Treated Cases of nmCRPC by Line of Therapies in Italy (2017–2030)

Table 45: Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)

Table 46: Total Treated Cases of mCRPC by Line of Therapies in Italy (2017–2030)

Table 47: Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 48: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 49: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (

Table 50: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)

Table 51: Total Metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)

Table 52: Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Table 53: Total Treated Cases of nmCRPC by Line of Therapies in Spain (2017–2030)

Table 54: Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)

Table 55: Total Treated Cases of mCRPC by Line of Therapies in Spain (2017–2030)

Table 56: Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–20

Table 57: Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

Table 58: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the Uni

Table 59: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–203

Table 60: Total Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)

Table 61: Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Table 62: Total Treated Cases of nmCRPC by Line of Therapies in the United Kingdom (2017–2

Table 63: Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)

Table 64: Total Treated Cases of mCRPC by Line of Therapies in the United Kingdom (2017–20

Table 65: Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 66: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 67: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (

Table 68: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)

Table 69: Total Metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)

Table 70: Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Table 71: Total Treated Cases of nmCRPC by Line of Therapies in Japan (2017–2030)

Table 72: Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)

Table 73: Total Treated Cases of mCRPC by Line of Therapies in Japan (2017–2030)

Table 74: Marketed Key Cross of Prostate Cancer

Table 75: Xofigo (radium Ra 223 dichloride), Clinical Trial Description, 2020

Table 76: Xtandi (Enzalutamide), Clinical Trial Description, 2020

Table 77: Erleada (apalutamide), Clinical Trial Description, 2020

Table 78: Jevtana (cabazitaxel), Clinical Trial Description, 2020

Table 79: Nubeqa (darolutamide), Clinical Trial Description, 2020

Table 80: Lynparza (olaparib), Clinical Trial Description, 2020

Table 81: Opdivo (nivolumab), Clinical Trial Description, 2020

Table 82: 177Lu-PSMA-617, Clinical Trial Description, 2020

Table 83: Relugolix, Clinical Trial Description, 2020

Table 84: HC-1119, Clinical Trial Description, 2020

Table 85: Seviteronel (VT-464), Clinical Trial Description, 2020

Table 86: PROSTVAC-VF, Clinical Trial Description, 2020

Table 87: ODM-208, Clinical Trial Description, 2020

Table 88: IMMU-132 (Sacituzumab govitecan), Clinical Trial Description, 2020

Table 89: Keytruda (Pembrolizumab/MK-3475), Clinical Trial Description, 2020

Table 90: Ipatasertib (RG7440), Clinical Trial Description, 2020

Table 91: Talazoparib, Clinical Trial Description, 2020

Table 92: Capivasertib (AZD5363), Clinical Trial Description, 2020

Table 93: AZD4635, Clinical Trial Description, 2020

Table 94: PRX302 (topsalysin), Clinical Trial Description, 2020

Table 95: Pamiparib (BGB-290), Clinical Trial Description, 2020

Table 96: Enoblituzumab (MGA271), Clinical Trial Description, 2020

Table 97: Tisotumab Vedotin, Clinical Trial Description, 2020

Table 98: Dupilumab, Clinical Trial Description, 2020

Table 99: Rubraca (Rucaparib), Clinical Trial Description, 2020

Table 100: Niraparib, Clinical Trial Description, 2020

Table 101: Proxalutamide (GT0918), Clinical Trial Description, 2020

Table 102: Abemaciclib (LY2835219), Clinical Trial Description, 2020

Table 103: Tomivosertib (eFT508), Clinical Trial Description, 2020

Table 104: Onvansertib, Clinical Trial Description, 2020

Table 105: RV001V, Clinical Trial Description, 2020

Table 106: ProstAtak, Clinical Trial Description, 2020

Table 107: 7MM Market Size of Prostate Cancer in USD Million (2017–2030)

Table 108: 7MM Market Size of Prostate Cancer by Types, in USD Million (2017–2030)

Table 109: 7MM Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 110: 7MM Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 111: United States Market Size of Prostate Cancer by Types, in USD Million (2017–203

Table 112: United States Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 113: United States Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 114: Germany, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 115: Germany Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 116: Germany Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 117: France, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 118: France Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 119: France Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 120: Italy, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 121: Italy Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 122: Italy Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 123: Spain, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 124: Spain Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 125: Spain Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 126: United Kingdom, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 127: United Kingdom Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 128: United Kingdom Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 129: Japan, Market Size of Prostate Cancer, in USD Million (2017–2030)

Table 130: Japan Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 131: Japan Market Size of CRPC by Therapies, in USD Million (2017–2030)

Table 132: National Institute for Health and Care Excellence (NICE) Decisions for Prostate

Table 133: Haute Autorité de santé (HAS) Decisions for Prostate Cancer Therapies

Table 134: IQWiG Decisions for Prostate Cancer Therapies



List of Figures:

Figure 1: Prostate Cancer SWOT Analysis

Figure 2: Prostate Cancer

Figure 3: Sign and Symptoms of Prostate Cancer

Figure 4: Risks Factors of Prostate Cancer

Figure 5: Pathophysiology of Prostate Cancer

Figure 6: Progression of Prostate Cancer and the Development of mCRPC

Figure 7: Diagnosis of Prostate Cancer

Figure 8: Gleason Score of Prostate Cancer

Figure 9: Global Heat Map of Prostate Cancer

Figure 10: Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Figure 11: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)

Figure 12: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)

Figure 13: Total Metastatic Cases of CSPC/HSPC and CRPC in the 7MM (2017–2030)

Figure 14: Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Figure 15: Total Treated Cases of nmCRPC by Line of Therapies in the 7MM (2017–2030)

Figure 16: Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)

Figure 17: Total Treated Cases of mCRPC by Line of Therapies in the 7MM (2017–2030)

Figure 18: Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Figure 19: Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Figure 20: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)

Figure 21: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)

Figure 22: Total Metastatic Cases of CSPC/HSPC and CRPC in the United States (2017–2030)

Figure 23: Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Figure 24: Total Treated Cases of nmCRPC by Line of Therapies in the United States (2017–2030)

Figure 25: Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)

Figure 26: Total Treated Cases of mCRPC by Line of Therapies in the United States (2017–2030)

Figure 27: Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 28: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 29: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)

Figure 30: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Germany (2017–2030)

Figure 31: Total Metastatic Cases of CSPC/HSPC and CRPC in Germany 2017–2030)

Figure 32: Total Treated Cases of nmHSPC/CSPC in Germany 2017–2030

Figure 33: Total Treated Cases of nmCRPC by Line of Therapies in Germany (2017–2030)

Figure 34: Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)

Figure 35: Total Treated Cases of mCRPC by Line of Therapies in Germany (2017–2030)

Figure 36: Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 37: Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 38: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)

Figure 39: Total Non-metastatic Cases of CSPC/HSPC and CRPC in France (2017–2030)

Figure 40: Total Metastatic Cases of CSPC/HSPC and CRPC in France2017–2030)

Figure 41: Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Figure 42: Total Treated Cases of nmCRPC by Line of Therapies in France (2017–2030)

Figure 43: Total Treated Cases of mHSPC/CSPC in France (2017–2030)

Figure 44: Total Treated Cases of mCRPC by Line of Therapies in France (2017–2030)

Figure 45: Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 46: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 47: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)

Figure 48: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Italy (2017–2030)

Figure 49: Total Metastatic Cases of CSPC/HSPC and CRPC in Italy 2017–2030)

Figure 50: Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Figure 51: Total Treated Cases of nmCRPC by Line of Therapies in Italy (2017–2030)

Figure 52: Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)

Figure 53: Total Treated Cases of mCRPC by Line of Therapies in Italy (2017–2030)

Figure 54: Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 55: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 56: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)

Figure 57: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)

Figure 58: Total Metastatic Cases of CSPC/HSPC and CRPC in Spain (2017–2030)

Figure 59: Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Figure 60: Total Treated Cases of nmCRPC by Line of Therapies in Spain (2017–2030)

Figure 61: Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)

Figure 62: Total Treated Cases of mCRPC by Line of Therapies in Spain (2017–2030)

Figure 63: Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 64: Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 65: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)

Figure 66: Total Non-metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)

Figure 67: Total Metastatic Cases of CSPC/HSPC and CRPC in the United Kingdom (2017–2030)

Figure 68: Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Figure 69: Total Treated Cases of nmCRPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 70: Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)

Figure 71: Total Treated Cases of mCRPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 72: Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 73: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 74: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)

Figure 75: Total Non-metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)

Figure 76: Total Metastatic Cases of CSPC/HSPC and CRPC in Japan (2017–2030)

Figure 77: Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Figure 78: Total Treated Cases of nmCRPC by Line of Therapies in Japan (2017–2030)

Figure 79: Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)

Figure 80: Total Treated Cases of mCRPC by Line of Therapies in Japan (2017–2030)

Figure 81: Localized Disease Treatment Algorithm

Figure 82: High-risk Localized and Locally Advanced Disease Treatment Algorithm

Figure 83: Metastatic Disease Treatment Algorithm

Figure 84: Suggested Treatment Paradigm for Molecular Biomarkers in Advanced Prostate Cancer

Figure 85: Summary of Recommendations

Figure 86: Unmet Needs

Figure 87: Major mechanisms of therapeutic resistance to androgen axis-targeting therapies in prostate cancer

Figure 88: Market Size of Prostate Cancer in the 7MM Countries in USD Million (2017–2030)

Figure 89: Market Size of CSPC by Therapies in the 7MM, in USD Millions (2017–2030)

Figure 90: Market Size of CRPC by Therapies in the 7MM, in USD Millions (2017–2030)

Figure 91: Market Size of Prostate Cancer in the United States, in USD Millions (2017–2030)

Figure 92: Market Size of CSPC by Therapies in the United States, in USD Millions (2017–2030)

Figure 93: Market Size of CRPC by Therapies in the United States, in USD Millions (2017–2030)

Figure 94: Market Size of Prostate Cancer in Germany, in USD Millions (2017–2030)

Figure 95: Market Size of CSPC by Therapies in Germany, in USD Millions (2017–2030)

Figure 96: Market Size of CRPC by Therapies in Germany, in USD Millions (2017–2030)

Figure 97: Market Size of Prostate Cancer in France, in USD Millions (2017–2030)

Figure 98: Market Size of CSPC by Therapies in France, in USD Millions (2017–2030)

Figure 99: Market Size of CRPC by Therapies in France, in USD Millions (2017–2030)

Figure 100: Market Size of Prostate Cancer in Italy, in USD Millions (2017–2030)

Figure 101: Market Size of CSPC by Therapies in Italy, in USD Millions (2017–2030)

Figure 102: Market Size of CRPC by Therapies in Italy, in USD Millions (2017–2030)

Figure 103: Market Size of Prostate Cancer in Spain, in USD Millions (2017–2030)

Figure 104: Market Size of CSPC by Therapies in Spain, in USD Millions (2017–2030)

Figure 105: Market Size of CRPC by Therapies in Spain, in USD Millions (2017–2030)

Figure 106: Market Size of Prostate Cancer in the United Kingdom, in USD Millions (2017–2030)

Figure 107: Market Size of CSPC by Therapies in the United Kingdom, in USD Millions (2017–2030)

Figure 108: Market Size of CRPC by Therapies in the United Kingdom, in USD Millions (2017–2030)

Figure 109: Market Size of Prostate Cancer in Japan, in USD Millions (2017–2030)

Figure 110: Market Size of CSPC by Therapies in Japan, in USD Millions (2017–2030)

Figure 111: Market Size of CRPC by Therapies in the Japan, in USD Millions (2017–2030)

Figure 112: Market Drivers

Figure 113: Market Barriers

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[前立腺がん治療薬の世界市場:インサイト・疫学・市場予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆